BASI:NSD-Bioanalytical Systems, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 6.49

Change

+0.26 (+4.17)%

Market Cap

USD 0.07B

Volume

0.07M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bioanalytical Systems, Inc., doing business as Inotiv, a pharmaceutical development company, provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical toxicology and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

-1.65 (-0.54%)

USD44.62B 69.79 40.40
IDXX IDEXX Laboratories, Inc

-0.35 (-0.08%)

USD38.11B 80.89 56.16
DXCM DexCom, Inc

-0.77 (-0.25%)

USD30.09B 129.45 78.92
EXAS Exact Sciences Corporation

-1.39 (-1.19%)

USD17.64B N/A N/A
GH Guardant Health, Inc

-0.36 (-0.32%)

USD11.30B N/A N/A
ICLR ICON Public Limited Company

+1.88 (+1.01%)

USD9.88B 31.56 21.32
QDEL Quidel Corporation

+6.32 (+3.62%)

USD7.34B 21.94 15.23
PRAH PRA Health Sciences, Inc

-1.03 (-0.93%)

USD7.13B 32.92 18.88
NTRA Natera, Inc

+1.53 (+1.84%)

USD7.09B N/A N/A
SYNH Syneos Health, Inc

-0.36 (-0.54%)

USD6.88B 35.52 20.06

ETFs Containing BASI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.11% 57% F 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.11% 57% F 74% C
Trailing 12 Months  
Capital Gain 38.09% 57% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.09% 57% F 75% C
Trailing 5 Years  
Capital Gain 316.00% 81% B- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 316.00% 81% B- 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 62.61% N/A N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.61% N/A N/A 94% A
Risk Return Profile  
Volatility (Standard Deviation) 94.05% N/A N/A 10% F
Risk Adjusted Return 66.57% N/A N/A 81% B-
Market Capitalization 0.07B 21% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 56.60 41% F 20% F
Price/Book Ratio 6.83 31% F 20% F
Price / Cash Flow Ratio 38.53 17% F 9% F
EV/EBITDA 42.88 27% F 19% F
Management Effectiveness  
Return on Equity -26.61% 51% F 32% F
Return on Invested Capital -0.66% 66% D 44% F
Return on Assets 0.43% 72% C- 49% F
Debt to Equity Ratio 128.58% 14% F 16% F
Technical Ratios  
Short Ratio 0.80 93% A 81% B-
Short Percent 0.15% 98% A+ 94% A
Beta 1.66 27% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector